Royalty Report: Drugs, Disease, Diagnostic – Collection: 221363


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Diagnostic
  • Hormones
  • Therapeutic
  • Biotechnology
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 221363

License Grant
The Germany Licensor grants to the Irsih Licensee the exclusive, non-assignableright and license to use the Licensor IPR Package:

(a) to Commercialize the Product in the Territory;

(b) to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and

(c) to Develop the Product for Commercialization in the Territory.

License Property
“Product” means any pharmaceutical product containing the API
“API” means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.

Macrilen™ (macimorelin) is an orally-active ghrelin agonist that stimulates the secretion of growth hormone. Macrilen™ (macimorelin) has been granted orphan drug designation by the FDA for the evaluation of growth hormone deficiency. On December 20, 2017, the FDA granted Licensor marketing approval for Macrilen™ (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”).

“Adult Indication” means assessing GHD in adults.

“GHD” means growth hormone deficiency.

AGHD reportedly affects approximately 60,000 adults across the U.S. and Canada. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.

Licensor Trademark” means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by the Licensor.

Field of Use
This agreement pertains to the drug industry relating the evaluation of growth hormone deficiency to be used in the diagnosis of patients with AGHD.  MACRILEN(macimorelin) is a prescription oral solution that is used to test for adult growth hormone deficiency (AGHD).

IPSCIO Record ID: 265296

License Grant
Irish Party A sold the United States and Canadian rights to Macrilenâ„¢ (macimorelin) under the License and Assignment Agreement to Party B for a payment plus tiered royalties on net sales and Party B will fund Party As Macrilenâ„¢(macimorelin) field organization as a contract field force to promote the product in the United States for up to three years.  Party A had a License and Assignment Agreement with Party C to to carry out development, manufacturing, registration, regulatory and supply chain services for the commercialization of Macrilenâ„¢ (macimorelin) in the U.S. and Canada. This agreement provides (i) for the 'right to use' license relating to the Adult Indication.
License Property
The Adult Indication is Macrilenâ„¢ (macimorelin), a ghrelin receptor agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The FDA has granted marketing approval for Macrilenâ„¢ (macimorelin) to be used in the diagnosis of adult growth hormone deficiency (AGHD).
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 27528

License Grant
The Company hereby grants to a Swiss company a sole and exclusive right and license including the right to sublicense others to register, use, sell and market Canada Products in Canada.
License Property
The term Canadian products shall mean the pharmaceutical products Activase, registered trademark, tissue plasminogen activator, Protropin, registered trademark, and Nutropin, registered trademark, human growth hormone, Actimmune, registered trademark, interferon gamma and Pulmozyme, registered trademark, dornase alpha each as sold in Canada.

Protropin® (somatrem for injection), is a polypeptide hormone produced by recombinant DNA technology. Protropin® (somatrem for injection) is indicated only for the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion. Skeletal Growth: Protropin stimulates skeletal growth in children with growth failure due to a lack of adequate secretion of endogenous growth hormone. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by growth hormone and one of its mediators, insulin-like growth factor-l. Serum levels of insulin-like growth factor-l are low in children and adolescents who are growth hormone deficient, but increase during treatment with Protropin. New bone is formed at the epiphyses in response to growth hormone. This results in linear growth until these growth plates fuse at the end of puberty.  Cell Growth: Treatment with pituitary-derived human growth hormone results in an increase in both the number and the size of skeletal muscle cells.

IPSCIO Record ID: 87659

License Grant
The license to be granted by Licensor to Licensee is a royalty-bearing license under all applicable patent and other proprietary rights of Licensee, including without limitation rights under the Technology and Licensee’s interest in the New Inventions and Joint Inventions to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) the Products in the Field in the Territory.

Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.

License Property
Product: Pharmaceutical formulations containing the Compound as an active ingredient and the Excipient.

Compound: Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.

Option Compound: Naltrexone and nalmephene/ nalmefene.

Naloxone is a medication used to block the effects of opioids, especially in overdose.[1] Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.

Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.

Field of Use
This agreement pertains to the treatment or prevention of any disease, disorder, state, condition or malady in humans except in the Opioid Field, provided that upon election of Opiant in writing and payment of the Option Fee, the “Field” shall include the Opioid Field.

Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.

Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.

IPSCIO Record ID: 264695

License Grant
This Agreement governs the Development and Commercialization of Combination Products for all Indications in the Field in the Territory.

The parties previously entered agreements to develop and commercialize IGF-1 in the United States and in all foreign countries.  The IGF-1 Agreements contain restrictions on each Partys ability to develop a combination product containing both human growth hormone and IGF-1.  This Agreement will collaborate in the development and commercialization of products containing both human growth hormone and IGF-1.

For the Exclusive/Co-Exclusive License, in the event of a Licensee Opt-In,  Licensor grants to a license, under the Licensor Patents and Licensor Know-How and Licensors interest in the Joint Patents and Joint Know-How, in all cases, to use, offer for sale, sell and import Combination Products in the Field in the Territory and otherwise perform its obligations and exercise its rights under this Agreement.

For the Non-Exclusive License,  in the event of a Licensee Manufacturing Opt-In,  Licensor automatically grants a non-exclusive, sublicensable (without any need for consent) license, under the Licensor Patents and Licensor Know-How;  Licensors interest in the Joint Patents and Joint Know-How;  the license granted to Licensee by Licensor under the previous agreements to Manufacture and import Combination Products;  Manufacture and import IGF-1 alone, BP3 alone, ALS alone and/or IGF-1 combined with BP3 and/or ALS, for use in the Manufacture of Combination Products; and perform research and development activities related to the Manufacture of Combination Products or the Manufacture of those compounds, in all cases, for use and sale within the scope of the license granted to Licensee.

For Joint Trademarks, Licensor automatically grants an exclusive license, under Licensors interest in the Joint Trademarks for Combination Products for such Indication, to use such Joint Trademarks for purposes of Developing and Commercializing Combination Products for such Indication in the Field in the Territory.

License Property
The Combination Product means a pharmaceutical formulation or product for use in the Field that contains GH and IGF-1 (including, without limitation, formulations and products containing GH and IGF-1 combined with BP3, IGF-1 combined with ALS or IGF-1 combined with BP3 and ALS) and that, in all cases, except for the purposes of the definitions of Phase I Clinical Trial and Phase II Clinical Trial, is administered either as a Pre-Mixed Formulation or single injection from a pre-filled, dual-chamber container-closure system (e.g., a syringe or vial). Combination Products include Short Stature Products and Non-Short Stature Products.

IGF-1 means native-sequence insulin-like growth factor-1 from any species with or without an N-terminal methionine, allelic variants thereof, and sequence variants thereof wherein substitutions and/or deletions are made in the region from 1 to 5 amino acids from the N-terminus of the mature native-sequence IGF-1 of any species, including des-IGF-1 and variants wherein at least the glutamic acid residue is absent at position 3 from the N-terminus of native-sequence human IGF-1.

There will be at least one Combination Product for Short Stature Indications (a Short Stature Product) and at least one Combination Product for the AGHD Indication and Other Indications (a Non-Short Stature Product).

A short Stature Product means a Combination Product for a Short Stature Indication.

Non-Short Stature Product means a Combination Product developed for an Indication other than a Short Stature Indication (i.e., for the AGHD Indication or an Other Indication) that contains a different concentration of GH and/or IGF-1 relative to the concentration of GH and/or IGF-1, respectively, in any Short Stature Product and/or a different ratio of GH to IGF-1 relative to the ratio of GH to IGF-1 in any Short Stature Product.

AGHD Indication means the Indication in which an adult patient has growth hormone deficiency as measured by a generally accepted growth hormone stimulation test, where such adult patient either has growth hormone deficiency, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy or trauma; or was growth hormone deficient during childhood as a result of congenital, genetic, acquired or idiopathic causes.

Licensor Patents means the rights granted by a Patent Office under a Patent Controlled by Licensor during the term of this Agreement (excluding Licensors interest in any Joint Patents), which Patent is necessary or used by Licensor for the Development, Manufacture or Commercialization of any Combination Product in the Field.

Licensor Know-How,, means Know-How (or, with reference to tangible substances, samples of Know-How) Controlled by Licensor during the term of this Agreement (excluding Licensors interest in any Joint Know-How) that is necessary or used by Licensor for the Development, Manufacture or Commercialization of any Combination Product in the Field.

Field of Use
The Field means all prophylactic, diagnostic and therapeutic uses in humans for any Indication. For clarity, Field does not include the Excluded Indications.  'Excluded Indications means any human disease, disorder or condition of the central nervous system (CNS) including, without limitation, CNS diseases and conditions arising out of Closed traumatic injury to head; Open traumatic injury to head; Traumatic or crush injury to spinal cord; Birth asphyxia; Perinatal asphyxia; In utero asphyxia; Toxic injury to brain; Near drowning; Acute meningitis (viral or bacterial); Post cardiac bypass surgery; Post extra corporeal membrane oxygenation; Anaesthetic maladventure; Carbon monoxide poisoning; Status epilepticus; Apparent life threatening event of infancy ( near miss cot death); Asphyxiation; Acute Encephalomyelitis; or, Multiple Sclerosis.

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.